B

    Beta Bionics, Inc. Common Stock (BBNX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $19.95
    +0.23 (+1.17%)

    Market Cap: $887.20M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(5/7)
    Avg Surprise
    -12.61%
    Streak
    5 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.51
    Range$-0.53 - $-0.49
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.53-3.3%
    60d ago$-0.53-3.3%
    30d ago$-0.53-3.3%
    7d ago$-0.53-3.3%
    Current$-0.51
    Revenue Consensus
    $35M
    Range$34M - $36M
    12 analysts
    Dec 31, 2026
    EPS Consensus$-0.37
    Range$-0.54 - $-0.21
    2 analysts
    Revenue Consensus
    $40M
    Range$39M - $42M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.37---
    Sep 26EST
    		-$-0.51---
    Jun 26
    		$-0.53$-0.62+14.52%Beat-96.3%
    Mar 26
    		$-0.36$-0.45+20.00%Beat+61.3%
    Dec 25
    		$-0.30$-0.38+21.05%Beat+89.0%
    Sep 25
    		$-0.33$-0.41+19.51%Beat+59.8%
    Jun 25
    		$-0.27$-0.47+42.55%Beat-
    Mar 25
    		$-0.93$-0.51-82.35%Miss-
    Dec 24
    		$-2.72$-1.22-123.56%Miss-
    Sep 24
    		$-0.82$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-13.13EV/EBITDAN/A
    Price/FCF-14.47xFCF Yield-6.91%
    Profitability
    Profit Margin-61.30%Operating Margin-79.90%
    ROE-26.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.88xQuick Ratio7.96x
    Trading Statistics
    BetaN/AAvg Volume1.22M
    52-Week High$32.7152-Week Low$8.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$19.52
    SMA 20$17.91
    SMA 50$16.77
    SMA 200$16.90
    EMA 10$19.21
    EMA 20$18.33
    EMA 50$16.74
    EMA 200$16.11

    MACD

    Line: 1.09Signal: 0.96Hist: 0.13

    ADX

    ADX: 30.8+DI: 27.4-DI: 12.9

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down20.0
    PSAR$18.97

    Bollinger Bands

    Upper Band$21.90
    Lower Band$13.92
    %B Position4452%(Upper)
    Band Width0.76

    RSI (14-Day)

    Neutral
    65.7

    Momentum Oscillators

    Stoch %K78.2
    Stoch %D78.2
    Williams %R-19.7
    ROC (10d)13.6%
    Momentum2.39
    CCI (20d)78.0
    MFI (14d)57.4

    Volatility Measures

    ATR (14d)$1.13(5.7%)
    StdDev (20d)1.99
    Hist Vol72.8%(High)

    Volume Flow

    VWAP$19.66
    OBV-33.3M
    AD Line-3.5M
    CMF (20d)0.446

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.4x(Low)
    VWMA (20d)$17.65

    Pivot Points

    R3$20.93
    R2$20.50
    R1$20.11
    Pivot Point$19.68
    S1$19.29
    S2$18.86
    S3$18.47

    Advanced Oscillators

    TSI26.23
    Ultimate Osc68.7
    KST224.01

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$32.01M$27.63M$32.12M$27.25M$23.24M$17.64M$20.44M$16.70M$15.05M$12.93M$8.35M$3.09M
    Cost of Revenue$13.11M$11.19M$13.18M$12.13M$10.73M$8.67M$8.75M$7.79M$6.96M$5.73M$3.29M$1.87M
    Gross Profit$18.90M$16.44M$18.94M$15.12M$12.50M$8.97M$11.69M$8.91M$8.08M$7.20M$5.06M$1.23M
    Operating Expenses$44.48M$40.71M$35.07M$32.16M$32.38M$27.61M$24.73M$19.89M$19.87M$16.65M$13.43M$10.01M
    R&D$10.24M$10.36M$10.13M$8.20M$8.87M$7.59M$9.21M$5.14M$6.35M$5.48M$4.46M$3.85M
    SG&A$9.60M$9.62M$8.60M$7.92M$7.88M$6.62M$4.71M$5.11M$4.54M$3.51M$3.35M$2.83M
    Operating Income$-25,578,000$-24,271,000$-16,124,000$-17,043,000$-19,872,000$-18,642,000$-13,037,000$-10,977,000$-11,784,000$-9,453,000$-8,367,000$-8,782,000
    Interest Income$2.18M$2.38M$2.66M$2.83M$3.00M$2.44M$951,000$826,000$993,000$1.14M$1.25M$0
    Interest Expense$0$0$0$0$0$10.01M$5.07M$0$2.68M$3.00M$55,000$0
    Income Before Tax$-23,401,000$-21,895,000$-13,465,000$-14,209,000$-16,869,000$-28,656,000$-18,106,000$-9,736,000$-14,463,000$-12,449,000$-18,848,000$-8,680,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-23,403,000$-21,895,000$-13,466,000$-14,209,000$-16,869,000$-28,656,000$-18,108,000$-9,736,000$-14,463,000$-12,449,000$-18,848,000$-8,680,000
    EBITDA$-24,365,000$-23,198,000$-15,125,000$-16,359,000$-20,035,000$-31,404,000$-18,528,000$-9,947,000$-14,880,000$-13,025,000$-18,556,000$-8,368,667
    EBIT$-25,578,000$-24,271,000$-16,123,000$-17,042,000$-19,874,000$-31,092,000$-19,057,000$-10,562,000$-15,456,000$-13,588,000$-18,848,000$-8,680,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BBNX

    News

    Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

    William Blair initiated coverage on Tandem Diabetes Care Inc. and Beta Bionics Inc., highlighting their efforts to expand into faster-growing segments of the insulin pump market, particularly for type 2 diabetes. While Beta Bionics is favored for its user-friendly algorithm and rapid expansion, Tandem, despite a slower projected growth rate, offers a more attractive valuation. Both companies are proactively addressing potential risks from future competitive bidding programs by focusing on pharmacy distribution and tubeless pump development.

    Sahm•8/22/26•
    Somewhat-Bullish

    William Blair initiates Beta Bionics stock rating at Market Perform

    William Blair has initiated coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating, citing the company's unique iLet insulin pump algorithm and strong revenue growth. While the stock is trading above its Fair Value according to InvestingPro, its pipeline development, including an expected entry into the patch pump market, and a strong balance sheet were highlighted as positive factors.

    Investing.com•8/22/26•
    Neutral

    Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

    William Blair has initiated coverage on Tandem Diabetes Care (TNDM) and Beta Bionics (BBNX), highlighting their roles in the growing insulin pump market, particularly in type 2 diabetes. While Beta Bionics receives an Outperform rating due to its user-friendly algorithm and strong sales trajectory, Tandem is rated Market Perform, with its lower valuation offsetting a projected slower growth rate. Both companies face potential pricing pressures from Medicare's competitive bidding program but are proactively shifting to pharmacy distribution and developing tubeless pumps.

    TradingView•8/21/26•
    Bullish

    Beta Bionics (NASDAQ:BBNX) Now Covered by William Blair

    William Blair has initiated coverage of Beta Bionics (NASDAQ:BBNX) with a "market perform" rating, contributing to the stock's "Moderate Buy" consensus and an average price target of $20.10. The company recently reported better-than-expected quarterly revenue of $32.01 million and an adjusted loss of $0.53 per share. Institutional investors like BlackRock and Vanguard have increased their stakes, while insiders have sold a total of 36,355 shares over the past 90 days.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    William Blair initiates Beta Bionics stock rating at Market Perform

    William Blair has initiated coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating, citing the company's unique AID algorithm and strong revenue growth. While the stock is currently trading above its Fair Value according to InvestingPro, Beta Bionics holds more cash than debt and plans to enter the patch pump market in 2027. Despite a recent earnings miss with a larger-than-expected loss per share, the company maintained its full-year outlook.

    Investing.com•8/21/26•
    Neutral

    Frequently Asked Questions About BBNX

    Does BBNX pay dividends?
    Beta Bionics, Inc. Common Stock (BBNX) does not currently pay a regular dividend.
    What is BBNX's market cap?
    Beta Bionics, Inc. Common Stock (BBNX) has a market capitalization of $887.20M with a current stock price of $19.95.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In